ABAlix Boisson

Alix Boisson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alix Boisson has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Marcel Yotebieng

    Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, United States

    5 shared publications
  • Bruce Fried

    Department of Health Policy and Management, Gillings School of Global Public Health, The University of North Carolina, Chapel Hill, USA

    4 shared publications
  • Patrick Ngimbi

    Affiliation Faculté de Médecine, Université Protestante au Congo, Kinshasa, Democratic Republic of the Congo

    4 shared publications
  • Peyton Thompson

    Division of Infectious Diseases, Department of Pediatrics, University of North Carolina, Chapel Hill, USA

    4 shared publications
  • Nana Mbonze

    Affiliation Faculté de Médecine, Université Protestante au Congo, Kinshasa, Democratic Republic of the Congo

    3 shared publications
  • Pélagie Babakazo

    École de Santé Publique de Kinshasa, Kinshasa, Democratic Republic of the Congo

    3 shared publications

Latest Publications

  • Open Access

    Perceived shifts in routine vaccine confidence during the COVID-19 pandemic in Kinshasa Province, DRC: A mixed-methods approach

    by Alix Boisson-Walsh, Patrick Ngimbi, Camille E. Morgan, Angela M. Stover, Nana Mbonze, Sarah Ntambua, Jolie Matondo, Marcel Yotebieng, Melchior M. Kashamuka, Linda James, et al.

    The COVID-19 pandemic negatively impacted routine immunizations worldwide, decreasing confidence in vaccination programs. We used mixed methods to examine changes in vaccine confidence from before to during the pandemic in HBV-negative adults in Kinshasa who were exposed to HBV in the household, and eligible for HBV vaccination. We measured changes in routine HBV vaccine confidence with a previously validated Shift in Vaccine Confidence (SVC) self-report measure that was verbally administered in Lingala (local language). We compared vaccination confidence before versus during the pandemic using Chi-square tests. We also interviewed participants and coded open-ended responses to the SVC scale to explore context-specific perceptions. From April 2022 to February 2023, we administered the SVC tool to a purposive sample of 41 participants: 7 vaccinees, 23 willing to receive HBV vaccine, and 11 refusers. Participants had a median age of 32 years, were predominantly affiliated with Revivalist churches, and most reported unemployment and no education beyond secondary school. We observed statistically significant declines across all five vaccine confidence domains when comparing responses before and during the pandemic (p < 0.01): vaccines prevent diseases (85.4%-68.3%), are safe (80.5%-46.3%), important for a child’s health (92.7%-87.8%) and one’s own health (87.8%-68.3%), and new vaccines carry no more risk than routine vaccines (78.1%-63.5%). Qualitative analysis identified four themes impacting uptake decisions: vaccine confidence, knowledge, risks, and external influences. Rising uncertainty about efficacy, safety, and distrust in the COVID-19 vaccine undermined vaccine confidence among our participants. Factors such as distrust in manufacturers and government, fear of side effects, perceived low illness risk, and inconvenient healthcare access contributed to low vaccine uptake. These insights underscore the pandemic’s impact on routine immunization and emphasize the need for consideration in future vaccination campaigns.


  • Open Access

    Assessing the feasibility of using publicly available data sources to identify healthcare data discrepancies and enhance service delivery: a retrospective cross-sectional study of four low human index scoring countries

    by Alix Boisson-Walsh, Jack Lewis, Matthew Neilson, Sheila Leatherman

    Introduction: Quality of care (QoC) remains a persistent challenge in countries with low Human Development Index scores (LHDIS) despite global efforts to promote universal health coverage. Addressing root causes and systematically implementing improvement interventions in LHDIS countries require a better understanding and use of QoC data. We aim to describe the data gaps and illustrate the state of quality in health services across a small set of countries. We demonstrate how we can leverage currently available, although imperfect, public data sources to compile quality metrics across multiple LHDIS countries. Methods: Using public data sources, the Demographic Health Survey (DHS) and Service Provision Assessment (SPA), we selected relevant quality metrics and categorised them within a QoC matrix. We based the selection of metrics on the quality of care in fragile, conflict-affected and vulnerable settings framework domains and the Donabedian model. Criteria for our retrospective cross-sectional study included a LHDIS and recent availability of both DHS and SPA data for data relevance. Results: The approach was feasible, with relevant indicators distributed across various QoC categories. However, some cells in the indicator matrix lacked suitable indicators from SPA and DHS data. We selected the Democratic Republic of the Congo, Haiti, Afghanistan and Senegal for a snapshot of QoC in LHDIS countries. Comparisons highlighted areas of positive performance and shared challenges across these countries, with notable variability in certain categories. Senegal ranked highest overall, while Afghanistan ranked lowest across all matrix categories. Senegal had the most comprehensive data, with 94.7% of metrics available. Missing data existed for two specific metrics in all four countries, particularly within the improving clinical care domain. Conclusion: The results are a clarion call for advancing efforts to develop standardised, publicly available, routinely collected and validated data sets to measure and publicly report LHDIS countries’ state of quality to marshal global attention and action in pursuit of more significant health equity.


  • Open Access

    Childhood immunization uptake determinants in Kinshasa, Democratic Republic of the Congo: ordered regressions to assess timely infant vaccines administered at birth and 6-weeks

    by Alix Boisson-Walsh, Peyton Thompson, Bruce Fried, Christopher Michael Shea, Patrick Ngimbi, Fidéle Lumande, Martine Tabala, Melchior Mwandagalirwa Kashamuka, Pélagie Babakazo, Marisa Elaine Domino, et al.


  • Open Access

    Advancing quality in low human development index scoring countries; the need for standardized and shared quality measurement and reporting

    by Sheila Leatherman, Alix J N Boisson-Walsh, Ezequiel Garcia Elorrio

    Sheila Leatherman, Alix Jn Boisson, Ezequiel Garcia Elorrio; Advancing quality in low human development index scoring (LHDIS) countries; the need for standardiz

  • Changes in hepatitis B vaccine perception in response to the COVID-19 pandemic: Development of the Shift in vaccine confidence (SVC) survey tool

    by Alix Boisson, Camille E. Morgan, Angela Stover, Patrick Ngimbi, Nana Mbonze, Sarah Ntambua, Jolie Matondo, Jonathan B. Parr, Marcel Yotebieng, Kashamuka Mwandagalirwa, et al.


  • Open Access

    Determinants of the uptake of childhood immunization in Kinshasa Province, the DRC: ordered logit regression analyses to assess timely infant vaccines administered at birth and six-weeks of age.

    by Alix Boisson, Peyton Thompson, Bruce Fried, Christopher Michael Shea, Patrick Ngimbi, Fidele Lumande, Martine Tabala, Kashamuka Mwandagalirwa, Pélagie Babakazo, Marisa Elaine Domino, et al.

    Background: Despite global efforts to reduce preventable childhood illness by distributing infant vaccines, immunization coverage in sub-Saharan African settings remains low. Further, timely administration of vaccines at birth – tuberculosis (Bacille Calmette-Guérin [BCG]) and polio (OPV0) – remains inconsistent. Countries such as Democratic Republic of the Congo (DRC) prepare to add yet another birth-dose vaccine in their immunization schedule, but research is necessary to understand the determinants of current birth-dose vaccines’ timely administration. This study aims to improve current and future birth-dose immunization coverage by understanding determinants of infants receiving vaccinations within the national timeframe. Methods: The study used two ordered regression models to assess barriers to timely BCG and first round of hepatitis B (HepB3) immunization across multiple time points using the Andersen Behavioral Model to conceptualize determinants at various levels. The assessment leveraged survey data collected during a continuous quality improvement study (NCT03048669) conducted in 105 maternity centers throughout Kinshasa Province, DRC. The final sample included 2,398 (BCG analysis) and 2,268 (HepB3 analysis) women-infant dyads living with HIV. Results: Between 2016 and 2020, 1,981 infants (82.6%) received the BCG vaccine, and 1,551 (68.4%) received the first dose of HepB3 vaccine. Of those who received the BCG vaccine, 26.3, 43.5%, and 12.8% received BCG within 24 hours, between one and seven days, and between one and 14 weeks, respectively. Of infants who received the HepB3 vaccine, 22.4% received it within six weeks, and 46% between six and 14 weeks of life. Many factors were positively associated with BCG uptake, including higher maternal education, household wealth, higher facility general readiness score, and religious-affiliated facility ownership. The factors influencing HepB3 uptake included older maternal age, higher education level, household wealth, transport by taxi to a facility, higher facility general and immunization readiness scores, and religious-affiliated facility ownership. Conclusion: This study demonstrated that the study participants’ uptake of vaccines was consistent with the country average, but not in a timely manner. Various factors were associated with timely uptake of BCG and HepB3 vaccines. These findings suggest that investment to strengthen the vaccine delivery system might improve timely vaccine uptake and equity in vaccine coverage.


  • Open Access

    Barriers and facilitators to timely birth-dose vaccines in Kinshasa Province, the DRC: a qualitative study

    by Alix Boisson, Camille E. Morgan, Bruce Fried, Christopher M. Shea, Marcel Yotebieng, Patrick Ngimbi, Nana Mbonze, Kashamuka Mwandagalirwa, Pélagie Babakazo, Peyton Thompson

    Background: National vaccine policies across the world have successfully improved infant vaccine coverage, but birth-dose (BD) vaccine coverage remains low. Countries such as the Democratic Republic of the Congo (DRC) aim to include the hepatitis B birth-dose (HepB-BD) vaccine in their national immunization schedule. HepB-BD’s short window for administration – within 24 hours of delivery to prevent mother-to-child transmission – adds to the complexity of streamlined and timely BD vaccines. This study aims to identify and understand barriers and facilitators to timely delivery of BD vaccine in Kinshasa Province, DRC, through individuals’ accounts with different perspectives on the uptake of the BD vaccine in preparation for its future roll-out. Methods: We conducted semi-structured interviews in seven health facilities across Kinshasa Province from June to July 2021. We purposefully sampled health facilities from the provinces’ five most prominent facility types—private, public, Catholic, Protestant, and not-for-profit. We interviewed decision-makers and/or providers from various levels of the health care continuum, including midwives, immunization staff, heads of maternity and immunizations, and vaccine officials at the health zone and the Programme Elargi de Vaccination (PEV) to understand administrative barriers to BD vaccines. We also conducted interviews with expectant mothers to elicit knowledge and perceptions about infant vaccines. Results: We interviewed 30 participants (16 informants and 14 expectant mothers). Interviewees were recruited from 7 health facilities, 2 health zones, and PEV. Data analysis was guided by the Consolidated Framework for Implementation Research (CFIR). Our analysis identified 13 constructs (2-3 per domain) related to the success of timely and streamlined BD vaccines. We found significant barriers within and across each domain; most notably, the multi-dose vials of existing BD vaccines determining when facility staff could vaccinate newborns, often resulting in untimely vaccinations; logistical concerns with regular national vaccine stockouts and ability to store vaccines; complex and unsynchronized vaccine fees across facilities; inadequate communication across delivery and vaccination wards; and limited and at times incorrect understanding of vaccines among mothers and other community members. Conclusions: Using the CFIR framework, this study integrated perspectives from facility informants and expectant mothers to inform national policy and implementation of the HepB-BD in DRC. These stakeholder-driven findings should guide the streamlining of timely BD vaccinations upon HepB-BD implementation.


  • Open Access

    Scaling Up Public Health Interventions: Engaging Partners Across Multiple Levels

    by Jennifer Leeman, Alix Boisson, Vivian Go

    Advancing the science of intervention scale-up is essential to increasing the impact of effective interventions at the regional and national levels. In contrast with work in high-income countries (HICs), where scale-up research has been limited, researchers in low- and middle-income countries (LMICs) have conducted numerous studies on the regional and national scale-up of interventions. In this article, we review the state of the science on intervention scale-up in both HICs and LMICs. We provide an introduction to the elements of scale-up followed by a description of the scale-up process, with an illustrative case study from our own research. We then present findings from a scoping review comparing scale-up studies in LMIC and HIC settings. We conclude with lessons learned and recommendations for improving scale-up research.


  • Open Access

    Implementation Approaches for Introducing and Overcoming Barriers to Hepatitis B Birth-Dose Vaccine in sub-Saharan Africa

    by Alix Boisson, Varun Goel, Marcel Yotebieng, Jonathan B. Parr, Bruce Fried, Peyton Thompson

    In sub-Saharan Africa (SSA), chronic viral hepatitis B (HBV) affects more than 60 million people. Mother-to-child transmission is a major contributor to the ongoing HBV epidemic and yet only 11 of 54 (20.3%) SSA countries have introduced the birth dose of HBV vaccine (HepB-BD) into their regular immunization schedule. As more African countries adopt HepB-BD, implementation approaches must be targeted to ensure effective and timely HepB-BD delivery, especially in rural and under-resourced settings. We conducted a systematic literature review of published literature using PubMed. We included 39 articles published from January 2010 to August 2020, as well as gray literature, case studies, and research performed in SSA. We describe barriers to the uptake of HepB-BD in SSA at the policy, facility, and community levels and propose solutions that are relevant to stakeholders wishing to introduce HepB-BD. We highlight the importance and challenge of reaching infants who are born outside of health care facilities (i.e., home deliveries) with HepB-BD in partnership with community health workers. We also discuss the critical role of maternal education and community engagement in future HepB-BD scale-up efforts in SSA. Key Findings A review of 39 articles outlining the experience of introducing the hepatitis B birth-dose (HepB-BD) vaccine in low- and middle-income countries in sub-Saharan Africa identifies the potential barriers to the vaccine9s uptake. Empirical examples of policy makers targeting the mother9s role to increase uptake of HepB-BD vaccine at the community level are strikingly scarce, and efforts to leverage community-level resources and reach remote areas have been limited. Key Implications We provide solutions that must be adapted to the local context to overcome the barriers to HepB-BD uptake identified across policy, facility, and community levels. Synergy must exist between policy, facility, and community level implementation for sub-Saharan African countries to effectively implement a universal HepB-BD vaccine immunization policy. For sub-Saharan African country policy makers to effectively implement a universal HepB-BD immunization policy, synergy must exist between the policy-, facility-, and community-level efforts.